Summit American Diabetes Associations Annual Scientific Sessions Pre-Conference-Selected Abstracts
June 2006

Primary Objective: To explore the latest trends in diabetes treatment and identify new approaches to addressing unmet needs in diabetes management.

Objectives:

• To examine data emerging from the American Diabetes Association’s (ADA) 66th Annual Scientific Sessions
• To investigate strengths and weaknesses associated with diabetes treatments currently in development
• To prioritize treatment objectives for diabetic patients

Products Highlighted:

• Vildagliptin (Galvus)—Novartis
• Sitagliptin (Januvia)—Merck
• Rimonabant (Acomplia)—Sanofi-Aventis
• Liraglutide—Novo Nordisk
• Technosphere Insulin System—MannKind Corporation

Topics:

• Issues that piqued physician interest at the ADA’s Annual Scientific Sessions
• Priorities in diabetes treatment
• Differences in DPP-IV inhibitor efficacy
• Physician satisfaction wih inhaled insulin products
• Continuous glucose monitoring

• “The chief topics of interest are advances and uses of..."
• “I do not see XX as a better agent.”
• “I believe in couple of years all patients who use pumps would use XXX at the same time.”

• Extensively published endocrinologists (n=9), all affiliated with centers of excellence in diabetes care.